(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/137085 A1

(51) International Patent Classification:
C07D 403/14 (2006.01) *C07D 413/14* (2006.01)
A61P 37/00 (2006.01) *C07D 491/107* (2006.01)
C07D 401/14 (2006.01) *A61K 31/4196* (2006.01)

(21) International Application Number:
PCT/IB2021/062029

(22) International Filing Date:
20 December 2021 (20.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/128,949 22 December 2020 (22.12.2020) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **CARCACHE, David**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **GRUBER, Florian**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **GUERINI, Danilo**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **GUNZENHAUSER, Martin**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **HENG, Richard**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **PERRUCCIO, Francesca**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **SIMIC, Oliver**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **SPANKA, Carsten**; Novartis Pharma AG, Postfach, 4002 Basel (CH).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2022/137085 A1

(54) **Title:** INDOLE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS



(I)

(57) **Abstract:** The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R_1 through R_8 are as defined herein, and methods of making and using the same.